<DOC>
	<DOCNO>NCT02716792</DOCNO>
	<brief_summary>This study evaluate renal function participant metastatic bone disease due breast cancer receive intravenous ( IV ) infusion ibandronate ( Bondronat ) 6 milligram ( mg ) , either 15 minute 60 minute , every 3 week . Efficacy safety ibandronate 2 group participant also compare . The anticipated time study treatment 7 month , target sample size 318 individual .</brief_summary>
	<brief_title>A Study Evaluate Renal Safety Intravenous Ibandronate ( Bondronat ) Participants With Metastatic Bone Disease Due Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>For participant childbearing potential : negative pregnancy test ready use effective contraceptive measure Metastatic breast cancer least one bone metastasis Karnofsky index &gt; /= 60 Life expectancy &gt; /= 6 month Estimated creatinine clearance ( Cockcroft Gault formula ) &gt; /= 30 milliliter per minute ( mL/min ) Pregnancy breast feeding participant Participant current dental problem , particularly tooth jaw infection , trauma surgery tooth jaw previous six week , medical history jaw osteonecrosis delay heal dental surgery Participant participating participate last 30 day clinical trial investigate treatment Uncontrolled brain metastasis Severe concomitant infection Known medical history systemic disease renal lesion Rapidly progress renal failure inclusion Uncontrolled cardiac disorder Hypercalcaemia ( &gt; 2.7 millimoles per liter [ mmol/L ] ) , hypocalcaemia ( &lt; 2 mmol/L ) Participant receive nephrotoxic chemotherapy Participant eligible haematopoietic stem cell transplantation inclusion time Bisphosphonate therapy 3 week randomization Known hypersensitivity ibandronate bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>